

**GlaxoSmithKline Pharmaceuticals Limited**

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030  
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024**

(Rs. in Lakhs)

	Particulars	3 months ended	Preceeding 3	Corresponding 3	9 months ended	9 months ended	Year ended
		31.12.2024	months ended	months ended	31.12.2024	31.12.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Income						
1	Revenue from operations	94636	100005	80498	275741	249638	340725
2	Other income	3506	3219	2834	10310	9361	12348
3	<b>Total Income (1+2)</b>	<b>98142</b>	<b>103224</b>	<b>83332</b>	<b>286051</b>	<b>258999</b>	<b>353073</b>
	Expenses						
	(a) Cost of materials consumed	9193	13725	8752	36251	31270	50499
	(b) Purchases of stock-in-trade	16423	21674	16252	55371	59734	85308
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	9528	2262	6393	10464	2926	(6964)
	(d) Employee benefits expense	12474	15071	14135	42673	45156	62439
	(e) Finance costs	9	27	32	73	103	180
	(f) Depreciation and amortisation expense	1880	1686	1711	5207	5158	6968
	(g) Other expenses	18000	15378	13215	47127	46018	59378
4	<b>Total expenses</b>	<b>67507</b>	<b>69823</b>	<b>60490</b>	<b>197166</b>	<b>190365</b>	<b>257808</b>
5	<b>Profit before exceptional items and tax (3-4)</b>	<b>30635</b>	<b>33401</b>	<b>22842</b>	<b>88885</b>	<b>68634</b>	<b>95265</b>
6	Exceptional items [credit/(charge)] (Refer Note 2)	-	469	(16331)	469	(14601)	(14361)
7	<b>Profit before tax (5+6)</b>	<b>30635</b>	<b>33870</b>	<b>6511</b>	<b>89354</b>	<b>54033</b>	<b>80904</b>
8	Tax expense						
	(a) Current tax	7305	9746	3132	23384	17455	23571
	(b) Deferred tax	472	(745)	(1170)	78	(2583)	(1136)
9	<b>Profit for the period/year (7-8)</b>	<b>22858</b>	<b>24869</b>	<b>4549</b>	<b>65892</b>	<b>39161</b>	<b>58469</b>

**GlaxoSmithKline Pharmaceuticals Limited**

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030  
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024**

**(Rs. in Lakhs)**


	Particulars	3 months ended 31.12.2024	Preceeding 3 months ended 30.09.2024	Corresponding 3 months ended 31.12.2023	9 months ended 31.12.2024	9 months ended 31.12.2023	Year ended 31.03.2024	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
10	Other comprehensive income							
	(i) Items that will not be reclassified to profit or loss	157	-	(466)	157	(466)	(557)	
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(39)	-	118	(39)	118	140	
11	<b>Total comprehensive income for the period (9+10)</b>	<b>22976</b>	<b>24869</b>	<b>4201</b>	<b>66010</b>	<b>38813</b>	<b>58052</b>	
	Paid-up equity share capital (face value per share Rs. 10)	16941	16941	16941	16941	16941	16941	
	Other equity						161468	
	Earnings per share (EPS) (of Rs. 10 each)							
	Basic and diluted EPS before Exceptional items (Rs.)	13.49	14.45	9.88	38.66	29.54	40.83	
	Basic and diluted EPS after Exceptional items (Rs.)	13.49	14.68	2.69	38.89	23.12	34.51	
		Not Annualised						

**Notes:**

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 14th February 2025. The Statutory auditors have carried out a limited review of the standalone financial results for the quarter and nine months ended 31st December 2024.
2. Exceptional items pertaining to the period / year :
  - (a) Exceptional items credit for the nine months ended 31st December 2024 of Rs.469 lakhs is on account of profit on sale of surplus residential properties and for the quarter and nine months ended 31st December 2023 of Rs. 16331 lakhs is on account of one off VRS (Voluntary Retirement Scheme) cost including other employee dues of Rs. 5537 lakhs. Additionally exceptional items charge for the nine months ended 31st December 2023 also includes profit on sale of surplus residential properties of Rs. 1730 lakhs.
  - (b) Exceptional items charge for the year ended 31st March 2024 of Rs.14361 lakhs is on account of charge of Rs. 16331 lakhs on account of one off VRS (Voluntary Retirement Scheme) cost including other employee dues of Rs. 5537 lakhs and profit on sale of surplus residential properties of Rs. 1970 lakhs.
3. Dividend of Rs. 20329 lakhs has been paid during the current quarter ended 31st December 2024 consequent to the Board of Directors declaring special interim dividend of Rs. 12 per equity share which had been approved by the Board in the meeting held on 29th October 2024.
4. The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.

14th February, 2025

By Order of the Board



Bhushan Akshikar  
Managing Director  
DIN: 09112346